Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
128.12
+0.08 (0.06%)
At close: Apr 28, 2026, 4:00 PM EDT
128.00
-0.12 (-0.09%)
After-hours: Apr 28, 2026, 5:21 PM EDT
Neurocrine Biosciences Revenue
In the year 2025, Neurocrine Biosciences had annual revenue of $2.86B with 21.45% growth. Neurocrine Biosciences had revenue of $805.50M in the quarter ending December 31, 2025, with 28.33% growth.
Revenue (ttm)
$2.86B
Revenue Growth
+21.45%
P/S Ratio
4.51
Revenue / Employee
$1,430,250
Employees
2,000
Market Cap
12.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 505.20M | 21.45% |
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Hims & Hers Health | 2.35B |
NBIX News
- 6 days ago - Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 14 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results - PRNewsWire
- 14 days ago - Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR - PRNewsWire
- 16 days ago - Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia - GlobeNewsWire
- 21 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 22 days ago - Neurocrine Biosciences Transcript: M&A announcement - Transcripts
- 22 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 22 days ago - This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barrons